McCready VR (2017) Radioiodine – the success story of Nuclear Medicine: 75th Anniversary of the first use of Iodine-131 in humans. Eur J Nucl Med Mol Imaging 44(2):179–182

Article  PubMed  Google Scholar 

Happel C, Kranert WT, Bockisch B et al (2022) The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules. Sci Rep 12(1):13925

Article  CAS  PubMed  PubMed Central  Google Scholar 

Happel C, Bockisch B, Leonhäuser B et al (2023) The influence of thionamides on intra-thyroidal uptake of 131I during radioiodine-131 treatment of Graves’ disease. Sci Rep 13(1):21190

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michalski K, Mix M, Meyer PT et al (2019) Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: A retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Nuklearmedizin 58(6):443–450

Article  PubMed  Google Scholar 

Sabet A, Haug AR, Eiden C et al (2017) Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging 7(2):74–83

CAS  PubMed  PubMed Central  Google Scholar 

Leonhäuser B, Happel C, Gröner D et al (2019) Evaluation of intratherapeutic 177Lu-HA-DOTATATE treatment in neuroendocrine tumors: Dosimetry with SPECT, whole-body imaging and gamma probe. Nuklearmedizin 58(5):379–386

Article  PubMed  Google Scholar 

Groener D, Baumgarten J, Haefele S et al (2021) Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers (Basel) 13(16):4017

Article  CAS  PubMed  Google Scholar 

Groener D, Nguyen CT, Baumgarten J et al (2021) Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res 11(1):61

Article  CAS  PubMed  PubMed Central  Google Scholar 

Groener D, Wichert J, Adams M et al (2023) Impact of [177Lu]Lu-PSMA-617 radioligand therapy on reference organ uptake assessed by [68Ga]Ga-PSMA-11-PET/CT. Cancers (Basel) 15(15):3878

Article  CAS  PubMed  Google Scholar 

Baumgarten J, Groener D, Nguyen Ngoc C et al (2022) Safety and efficacy of 177Lutetium-PSMA-617 radioligand therapy shortly after failing 223Radium-Dichloride. Cancers (Basel) 14:557

Article  CAS  PubMed  Google Scholar 

Bastian MB, Sieben M, Blickle A et al (2024) Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-024-07006-z. Online ahead of print

Article  PubMed  PubMed Central  Google Scholar 

Hänscheid H, Lapa C, Buck AK et al (2017) Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC. Nuklearmedizin 56(6):219–224

Article  PubMed  Google Scholar 

Kratochwil C, Fendler WP, Eiber M et al (2023) Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 50(9):2830–2845

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fitschen J, Knoop BO, Behrendt R et al (2011) External radiation exposure and effective half-life in Lu-177-Dota-Tate therapy. Z Med Phys 21(4):266–273

Article  PubMed  Google Scholar 

Kratochwil C, Fendler WP, Eiber M et al (2019) EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 46(12):2536–2544

Article  PubMed  Google Scholar 

Kranert WT, Bockisch B, Wichert J et al (2022) Anticipating criteria for discharge after Lu-177-PSMA treatment - discussion of several scenarios. Nuklearmedizin 61(2):111–119

PubMed  Google Scholar 

Khawar A, Eppard E, Sinnes JP et al (2018) Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma. Clin Nucl Med 43(7):486–491

Article  PubMed  Google Scholar 

Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209

Article  CAS  PubMed  Google Scholar 

Kotzerke J, Böhmer D, Schlomm T et al (2018) PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection. Nuklearmedizin 57(3):69–73

PubMed  Google Scholar 

Herrmann K, Bluemel C, Weineisen M et al (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56(6):855–861

Article  CAS  PubMed  Google Scholar 

Yordanova A, Eppard E, Kürpig S et al (2017) Theranostics in nuclear medicine practice. Onco Targets Ther 10:4821–4828

Article  PubMed  PubMed Central  Google Scholar 

Turner JH (2018) An introduction to the clinical practice of theranostics in oncology. Br J Radiol 91(1091):20180440

Article  PubMed  PubMed Central  Google Scholar 

Rinscheid A, Kletting P, Eiber M et al (2019) Technical note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu-PSMA therapy. Med Phys 46(12):5861–5866

Article  CAS  PubMed  Google Scholar 

Baum RP, Kulkarni HR, Schuchardt C et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. J Nucl Med 57(7):1006–1013

Article  CAS  PubMed  Google Scholar 

Mhawech-Fauceglia P, Zhang S, Terracciano L et al (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 50(4):472–483

Article  CAS  PubMed  Google Scholar 

Delker A, Fendler WP, Kratochwil C et al (2016) Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43(1):42–51

Article  CAS  PubMed  Google Scholar 

Heck MM, Retz M, Tauber R et al (2017) PSMA-targeted radioligand therapy in prostate cancer. Urologe A 56(1):32–39

Article  CAS  PubMed  Google Scholar 

Yordanova A, Becker A, Eppard E et al (2017) The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging 44(9):1473–1479

Article  CAS  PubMed  Google Scholar 

Bastian MB, Sieben M, Burgard C et al (2024) Outcome and renal safety of PSMA-targeted radioligand therapy in mCRPC patients with preexisting impaired renal function. Clin Nucl Med. https://doi.org/10.1097/RLU.0000000000005583. Online ahead of print

Article  PubMed  Google Scholar 

Cremonesi M, Ferrari ME, Bodei L et al (2018) Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 45(13):2426–2441

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thorwarth D, Notohamiprodjo M, Zips D et al (2017) Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. Z Med Phys 27(1):21–30

Article  PubMed